

REAL-WORLD STUDY OF APALUTAMIDE TREATMENT IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER IN NINE HOSPITALS OF VALENCIAN COMMUNITY.

, F. RODRIGUEZ-LUCENA (1) J. POQUET-JORNET (2), F. MENDOZA-OTERO (3), J. POLACHE-VENGUD (4), M. DÍAZ-GONZÁLEZ (5), M.A. BERNABEU-MARTINEZ (6), M. LLINARES-ESQUERDO (2), R. GARCIA-GARCIA (7), N. GARCIA DEL BUSTO (8), A.GARCIA-MONSALVE (9).

(1) HOSPITAL VEGA BAJA, ORIHUELA, SPAIN. (2) HOSPITAL DE DENIA, DENIA, SPAIN (3) HOSPITAL GENERAL UNIVERSITARIO DE ELDA,, ELDA, SPAIN. (4) HOSPITAL GENERAL UNIVERSITARIO DR. BALMIS, ALICANTE, SPAIN. . (5) HOSPITAL MARINA BAIXA, VILA JOIOSA, SPAIN (6) HOSPITAL UNIVERSITARIO SAN JUAN, SAN JUAN, SPAIN. (7) HOSPITAL UNIVERSITARIO DE TORREVIEJA,, TORREVIEJA, SPAIN. . (8) HOSPITAL VIRGEN DE LOS LIRIOS, ALCOY, SPAIN. (9) HOSPITAL GENERAL UNIVERSITARIO DE ELCHE, ELCHE, SPAIN.

Background and Importance

Systemic involvement of prostate cancer(PC) typically occurs at the bone level (65-85%). Patients with metastatic hormone-sensitive prostate cancer(mHSPC) have survival rates ranging from 1-6 years, depending on high-risk prognostic factors such as:

- Elevated levels of prostate-specific antigen(PSA>20) at diagnosis.
- High Gleason score(8-10).
- Increased volume of metastatic disease.
- Poor functional status.
- Bone symptoms or the presence of visceral metastases.

Apalutamide, abiraterone, and enzalutamide are orally administered treatments financed for use in combination with androgen deprivation therapy. They have demonstrated improvement in overall survival (OS), particularly in high-risk progression populations, and a favorable safety profile.


Aim and Objectives

Study to asses the efficacy profile, safety and clinical follow-up of patients with mHSPC undergoing Apalutamide treatment.

Materials and Methods

- ✓ Retrospective observational study approved by the Drug Research Ethics Committee (CEIm).
- ✓ Patients with mHSPC who initiated with Apalutamide in 9 public hospitals in Valencian Community, Spain.
- ✓ Minimum clinical follow-up of 6 months as of March 2023.
- ✓ Clinical records, PSA evolution, and toxicity reported by healthcare professionals or the patients themselves were reviewed.
- ✓ A comprehensive descriptive statistical analysis was conducted, both overall and by disease volume.

Results



Conclusion and Relevance

- ✓ We did **not** observe **significant** response **differences** between **low** and **high volume** groups.
- ✓ **Apalutamide** in **real-world treatment** of men with mHSPC demonstrates a **favorable safety profile** like data published in clinical trials.

References and/or acknowledgements

Cornford, Philip & Bergh, Roderick & Briers, et al. (2020). EAU-EANM-ESTRO-ESUR SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology. 79.10.1016/j.eururo.2020.09.046.

